Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma

Thursday, June 2, 2011 General News
Email Print This Page Comment bookmark
Font : A-A+

Clinical Study Seeks to Evaluate MORAb-004 as a Single Agent for Extending Progression-Free Survival of Patients with Metastatic Disease

Contacts:  

Media Inquiries

Investor Inquiries

Terry Cushmore

Rod Dausch

Morphotek, Inc.

Morphotek, Inc.

610-423-6197

610-423-6111

tcushmore@morphotek.com

Dausch@morphotek.com

Media Inquiries

Investor Inquiries

Lynn Kenney

Alex Scott

Eisai Inc.

Eisai Inc.

201-746-2294

201-746-2177

lynn_kenney@eisai.com

alex_scott@eisai.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook